IN-HOSPITAL AND 30-DAY PACEMAKER LEAD OUTCOMES IN PATIENTS UNDERGOING TRANSCATHETER TRICUSPID VALVE REPLACEMENT

Authors

• Felix Nguyen, Henry Ford HealthFollow
• Chaun Gandolfo, Henry Ford HealthFollow
• Gautam Rangavajla, Henry Ford HealthFollow
• Gennaro Giustino, Henry Ford HealthFollow
• Jonathan X. Fang, Henry Ford HealthFollow
• Hussayn Alrayes, Henry Ford HealthFollow
• Leo Kar Lok Lai, Henry Ford HealthFollow
• Georgi Fram, Henry Ford HealthFollow
• Karl J. Ilg, Henry Ford HealthFollow
• Joshua Greenberg, Henry Ford HealthFollow
• John Dawdy, Henry Ford HealthFollow
• Pedro Engel Gonzalez, Henry Ford HealthFollow
• Pedro A. Villablanca, Henry Ford HealthFollow
• James C. Lee, Henry Ford HealthFollow
• Bryan Zweig, Henry Ford HealthFollow
• William W. O’Neill, Henry Ford HealthFollow
• Tiberio M. Frisoli, Henry Ford HealthFollow
• Brian P. O’Neill, Henry Ford HealthFollow

Recommended Citation

Nguyen F, Gandolfo C, Rangavajla G, Giustino G, Fang JX, Alrayes H, Kar Lok Lai L, Fram G, Ilg KJ, Greenberg J, Dawdy J, Engel Gonzalez P, Villablanca PA, Lee JC, Zweig B, O’Neill WW, Frisoli TM, O’Neill BP. IN-HOSPITAL AND 30-DAY PACEMAKER LEAD OUTCOMES IN PATIENTS UNDERGOING TRANSCATHETER TRICUSPID VALVE REPLACEMENT. J Am Coll Cardiol 2025; 85(12):829.

Document Type

Conference Proceeding

Publication Date

4-1-2025

Publication Title

J Am Coll Cardiol

Keywords

adverse device effect, artificial heart pacemaker, clinical article, conference abstract, coronary sinus, female, follow up, heart right atrium, human, impedance, implantable cardioverter defibrillator, male, New York Heart Association class, pacemaker electrode, therapy, tricuspid valve prosthesis, tricuspid valve regurgitation, tricuspid valve replacement

Abstract

Background: There has been increasing use of transcatheter tricuspid valve replacement (TTVR) to treat severe tricuspid regurgitation (TR). Many patients with severe TR have permanent pacemaker (PPM) or implantable cardiac defibrillator (ICD) leads. The impact of TTVR on jailed lead parameters out to 30 days is unknown. Methods Patients with PPM/ICDs undergoing TTVR with the commercial EVOQUE valve at Henry Ford Hospital from FebruarySeptember 2024 were included. Device interrogations were performed prior to TTVR, 24 hours after, and at 30 days. Lead-related outcomes including impedance, thresholds, dislodgements, and need for extraction were evaluated. Results 16 patients with PPM/ICDs underwent EVOQUE for severe TR, of which 11 had 30-day follow-up. Mean age was 82.1 years old. Mean NYHA Class was 2.8 ± 0.5. 14 patients had PPMs, 2 had ICDs. 15 patients had right atrial and right ventricular (RV) leads (94%), 1 had a His lead (6%), 7 had coronary sinus leads (44%). Average change in lead impedance at 24 hours compared to baseline was -6.72% ± 7.88%. In patients with 30-day follow-up, average change in lead impedance at 30-days was -3.16% ± 6.46%. Average change in RV thresholds at 30-days was 11.38% ± 25.56%. There were no lead dislodgements or need for lead extraction. Mild TR or better was achieved in 14 patients (88%). Conclusion There was a small change in PPM/ICD lead parameters out to 30 days after EVOQUE placement in this small cohort. Future studies with longer follow-up are needed. [Formula presented]

Volume

85

Issue

12

First Page

829